Published on 10/25/2006 in the Prospect News Biotech Daily.
VaxInnate secures $40 million in series C financing for flu vaccine development
By Lisa Kerner
Charlotte, N.C., Oct. 25 - VaxInnate Corp. said it completed a $40 million round of series C financing to develop vaccines for human and avian flu as well as prophylactic and therapeutic applications using its Toll-like receptor technology platform.
New Leaf Venture Partners led the round, joined by Canaan Partners and existing investors HealthCare Ventures, Oxford Bioscience Partners LLC, MedImmune Ventures, Inc. and CHL Medical Partners.
VaxInnate is a privately held biotechnology company based in Cranbury, N.J.
| Issuer: | VaxInnate Corp.
|
| Issue: | Series C financing
|
| Amount: | $40 million
|
| Investors: | New Leaf Venture Partners (lead), Canaan Partners, HealthCare Ventures, Oxford Bioscience Partners LLC, MedImmune Ventures, Inc., CHL Medical Partners
|
| Announcement date: | Oct. 25
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
